A novel therapy for Glioblastoma, the most common and most malignant form of brain tumor
| Reference number | |
| Coordinator | Glionova AB |
| Funding from Vinnova | SEK 4 950 000 |
| Project duration | January 2015 - December 2016 |
| Status | Completed |
Important results from the project
The concrete goal with this project is to compile a full GLP safety pharmacology and toxicology package for our candidate drug GLN-1001 (Vacquinol-1), in accordance with the regulatory requirements and therein to document an acceptable safety profile, justifying clinical trials with the intended doses.
Expected long term effects
The results of safety pharmacology and toxicological testing and further efficacy studies do not enable the start of clinical Phase I/II and proof of concept studies in patients.
Approach and implementation
A full GLP safety pharmacology and toxicology package in accordance with the regulatory requirements has been completed on time and on budget, involving internal resources as well as external CROs, Karolinska Institutet and Mayo Clinic.